ImmunoGen, Inc. logo


ImmunoGen, Inc.


Earnings Summary

Net Profits


Net Profits:

ImmunoGen, Inc.’s net profit fell -58.74% since last year same period to $-59.01Mn in the Q4 2022. On a quarterly growth basis, ImmunoGen, Inc. has generated 24.11% jump in its net profits since last 3-months.

Earnings per share (EPS) Estimates

Earnings per share (EPS) estimates of the ImmunoGen, Inc. post its latest quarter earnings

EPS Estimate Current Quarter
EPS Estimate Current Year


EPS Estimate Current Quarter:

ImmunoGen, Inc.’s earning per share (EPS) estimates for the current quarter stand at -0.29 - a -16% fall from last quarter’s estimates.

EPS Estimate Current Year:

ImmunoGen, Inc.’s earning per share (EPS) estimates for the current year stand at -0.29.

Key Ratios

Key ratios of the ImmunoGen, Inc. post its Q4 2022 earnings

Return on Assets (ROA)
Return on Equity (ROE)


Return on Assets (ROA):

Return on assets (ROA) indicates the profitability of the company in relation to its total assets. This ratio tells the financial health of the company. The higher the ROA, the better the company’s financial health. If any company has a ROA in the range of 5% to 20% - it is generally considered good. ROA above 20% is generally considered excellent. ImmunoGen, Inc.’s return on assets (ROA) stands at -0.32.

Earning Per Share (EPS):

The Return On Equity ratio indicates a company’s ability to turn equity capital received from shareholders into profits. ROE highlights the efficiency of equity capital in running the business. Generally, a return on equity in double digits is considered good. ImmunoGen, Inc.’s return on equity (ROE) stands at -0.93.

Earnings Calendar

Earnings DateEstimated EPSReported EPSSurprise %

Company Information

ImmunoGen is developing the next generation of antibody-drug conjugates to improve outcomes for cancer patients. By generating targeted therapies with enhanced anti-tumor activity and favorable tolerability profiles, the company aims to disrupt the progression of cancer and offer its patients more good days.

ImmunoGen, Inc.
830 Winter Street, Waltham, MA, United States, 02451-1477
Health Technology
Mark Enyedy